Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Oxaliplatin · Eloxatin, NUFOX

Small molecule · Cytotoxic, directed at DNA · developed by Sanofi Aventis Us

Approved FDA, Aug 2002
2 Registered trials

What is Oxaliplatin?

Oxaliplatin is an organoplatinum complex that is converted in physiologic solutions to reactive derivatives which form inter- and intrastrand platinum-DNA crosslinks. These crosslinks inhibit DNA replication and transcription in a cell-cycle nonspecific manner. It is studied in colorectal cancer and peripheral T-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Eloxatin, NUFOX, JM-83
Drug type
Small molecule
Targets
DNA
Mechanism
Cytotoxic, directed at DNA
Pathways
DNA replication inhibition, DNA transcription inhibition
Therapy area
Oncology
Developer
Sanofi Aventis Us
In trials of
IPHA, NCNA
FDA status
Approved as Eloxatin (August 9, 2002), NDA021492
UNII
04ZR38536J

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04984837 Phase 2 Peripheral T Cell Lymphoma Active not recruiting IPHA
NCT03428958 Phase 1/2 Colorectal Cancer Completed NCNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Peripheral T Cell LymphomaRelapse/RecurrenceColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsNeoplasms, Colorectal

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.